2-Methyl-4-propan-2-yl-6-(propan-2-yloxymethyl)morpholine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 2-Methyl-4-propan-2-yl-6-(propan-2-yloxymethyl)morpholine
• 英文别名: 2-methyl-4-propan-2-yl-6-(propan-2-yloxymethyl)morpholine
• 化学式: C₁₂H₂₅NO₂
• 分子量: 215.33
• InChiKey: CUCJRIAGCCQVTI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.7
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• BICYCLIC MORPHOLINO COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM
  申请人：Ionis Pharmaceuticals, Inc.

  公开号：US20160186175A1

  公开（公告）日：2016-06-30

  The present invention provides bicyclic morpholino compounds and oligomeric compounds prepared therefrom. More particularly, incorporation of one or more of the bicyclic morpholino compounds into an oligomeric compound is expected to enhance one or more properties of the oligomeric compound. Such oligomeric compounds can also be included in a double stranded composition. In certain embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.

  本发明提供双环吗啉化合物及其制备的寡聚化合物。更具体地，将一个或多个双环吗啉化合物并入寡聚化合物中，预计会增强寡聚化合物的一种或多种性质。此类寡聚化合物也可以包含在双链结构中。在某些实施例中，本发明提供的寡聚化合物预计会与目标RNA的一部分杂交，导致目标RNA的正常功能丧失。
• ANTISENSE COMPOUNDS TARGETING GENES ASSOCIATED WITH USHER SYNDROME
  申请人：Hastings Michelle L.

  公开号：US20140114057A1

  公开（公告）日：2014-04-24

  The present invention provides compounds comprising oligonucleotides complementary to an Usher transcript. Certain such compounds are useful for hybridizing to an Usher transcript, including but not limited, to an Usher transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the Usher transcript. In certain such embodiments, the Usher transcript includes a mutation that results in cryptic splicing and hybridization of the oligonucleotide results in a decrease in the amount of cryptic splicing. In certain embodiments, such compounds are used to treat Usher Syndrome.
• METHODS FOR MODULATING KALLIKREIN (KLKB1) EXPRESSION
  申请人：Revenko Alexey

  公开号：US20140206745A1

  公开（公告）日：2014-07-24

  Disclosed herein are methods for decreasing kallikrein and treating or preventing thromboembolic conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to kallikrein include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Methods for inhibiting kallikrein can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
• METHODS FOR MODULATING METASTASIS-ASSOCIATED-IN-LUNG-ADENOCARCINOMA-TRANSCRIPT-1 (MALAT-1) EXPRESSION
  申请人：Isis Pharmaceuticals, Inc.

  公开号：US20140371296A1

  公开（公告）日：2014-12-18

  The present embodiments provide compounds and methods for reducing expression of Metastasis-Associated-in-Lung-Adenocarcinoma-Transcript-1 (MALAT-1) RNA and/or protein in an animal. Such methods are useful for treating cancer, such as colon cancer, intestinal cancer, lung cancer (e.g. non-small cell lung cancer), liver cancer, and/or prostate cancer. In various aspects, the cancer is a primary cancer.
• MODULATION OF RNA BY REPEAT TARGETING
  申请人：Isis Pharmaceuticals, Inc.

  公开号：US20140378533A1

  公开（公告）日：2014-12-25

  Disclosed herein are antisense compounds, compositions and methods for modulating an RNA target by targeting a repetitive sequence in the RNA target and modulating an associated disease, disorder and/or condition related to such RNA target. Also disclosed herein are methods of identifying such compounds and compositions.